BioArctic AB 2024 AR2
The report highlights BioArctic's significant achievements in 2024, including the continued global launch of Leqembi (lecanemab) for early Alzheimer's disease, which is now approved in 42 countries. The company signed a major global exclusive license agreement with Bristol Myers Squibb for its BAN1503 and BAN2803 antibody programs, securing a USD 100 million upfront payment. Additionally, BioArctic initiated the EXIST Phase 2a study for exidavnemab in Parkinson's disease and presented promising preclinical data for its proprietary BrainTransporter technology. Financially, the company reported net revenues of SEK 257.4 million, driven by royalties from Leqembi sales.
Company: BioArctic AB
Sector: Professional & technical services
Country: Sweden
Year: 2024
Type: AR2
Pages: 150
Back to company
BioArctic AB
Annual Report
The report highlights BioArctic's significant achievements in 2024, including the continued global launch of Leqembi (lecanemab) for early Alzheimer's disease, which is now approved in 42 countries. The company signed a major global exclusive license agreement with Bristol Myers Squibb for its BAN1503 and BAN2803 antibody programs, securing a USD 100 million upfront payment. Additionally, BioArctic initiated the EXIST Phase 2a study for exidavnemab in Parkinson's disease and presented promising preclinical data for its proprietary BrainTransporter technology. Financially, the company reported net revenues of SEK 257.4 million, driven by royalties from Leqembi sales.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees